DERMA SCIENCES langfristiges Topinvest!

Derma Sciences potentially finds a way to help the body utilize its own stem cells more productively for wound healing.
www.dermasciences.com/dsc127/

Derma Sciences Reports Continued Healing at 24 Weeks in Patients with Diabetic Foot Ulcers Treated with DSC127 in Phase 2 Trial

Healing spread widens between DSC127 0.03% group and placebo group compared with 12-week data

Wounds up to five times more likely to heal at 24 weeks with DSC127 0.03% versus placebo
www.ir.dermasciences.com/profiles/investor/...40&BzID=1109

Derma Sciences First Quarter Results Feature Positive Cash Flow from Operations, Advanced Wound Care Product Sales up 57%, Total Sales up 12%
www.ir.dermasciences.com/profiles/investor/...40&BzID=1109

Derma Sciences Inc said foot ulcers in 85 percent of diabetic patients healed completely after being treated with its experimental drug at the end of a 24-week trial, improving its chances of licensing the drug to potential partners.
www.reuters.com/article/2011/05/25/...es-idUSTRE74O5JI20110525

Derma Sciences Reports Record Fourth Quarter Net Sales; Sales Force Expansion Ahead of Schedule; Continues Progress toward Phase 3 Trials

Conference call begins at 11:00 a.m. Eastern time today

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2011. Highlights of the fourth quarter of 2011 and recent weeks include:

   Net sales were $16.5 million, up 8% over the prior-year fourth quarter, while net sales for the year were $62.6 million, up 11% over 2010
   Advanced wound care product sales were $4.5 million for the fourth quarter of 2011, up 23% and were $15.9 million for the year, up 37% over the prior year
   Advanced wound care products accounted for 27% of net sales, up from 24% in the prior-year quarter
   Traditional wound care product sales for the quarter were $12.1 million, up 4% from $11.7 million in the prior year quarter
   Hired 10 advanced wound care sales representatives during the first quarter of 2012 for a total of 36 as of March 26th, well ahead of schedule
   Positive meeting with the U.S. Food and Drug Administration (FDA) regarding preparations to begin Phase 3 trials with DSC127 for the treatment of diabetic foot ulcers
   Fourth quarter 2011 net loss was $2.5 million, or $0.23 per share compared with $0.3 million, or $0.05 per share, in the prior year quarter as planned investments in sales force expansion and research and development added to expenses

Derma Sciences to Acquire MedEfficiency; Expands Proprietary Advanced Wound Care Product Offering with High-Growth, Market-Leading, Gold-Standard Treatment for Diabetic Foot Ulcers
www.ir.dermasciences.com/profiles/investor/...amp;Category=440

kauft noch mal 100.000 Stück für 9.25
finance.yahoo.com/q/it?s=DSCI+Insider+Transactions

amp2012.com/

Derma Sciences Announces Pricing of Underwritten Registered Direct Offering of Common Stock

Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per share. The offering is expected to close on or about April 5, 2012. Piper Jaffray & Co. is acting as the sole underwriter of the offering.

Net proceeds from the sale of the shares of common stock, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $17.9 million. The Company plans to use the net proceeds from the offering for the continued development of DSC127 and for general corporate purposes.

When available, copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained from the Securities and Exchange Commission at www.sec.gov, or from Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or email prospectus@pjc.com, or by telephone at (800) 747-3924.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.
www.ir.dermasciences.com/profiles/investor/...amp;Category=440

finance.yahoo.com/news/...es-hold-first-quarter-152200173.html

http://www.ariva.de/depot/private/positions.m?depot_id=417284

biz.yahoo.com/e/120605/dsci8-k.html

letztes billiges einsteigen ist angesagt...

Derma Sciences acquires long-term exclusive rights to NIMBUS technology
finance.yahoo.com/news/...es-acquires-long-term-113143297.html

Derma Sciences Reports Second Quarter 2012 Financial Results

-Advanced Wound Care Products up 52%; Represents 33% of Net Sales-

-DSC127 Drug Program on Track for Phase 3 Start by Year End-

Conference call begins at 11:00 a.m. Eastern time today
finance.yahoo.com/news/...eports-second-quarter-113000077.html

gehts bald rund Chartmäßig

Derma Sciences Launches MEDIHONEY® HCS in the U.S.

Novel Combination of MEDIHONEY® and XTRASORB® Hydrates Dry Wounds and Absorbs Fluid from Wounds that are Draining
finance.yahoo.com/news/...aunches-medihoney-hcs-113000429.html

Derma Sciences on Track to Begin Phase 3 Program with DSC127 in December Following Meeting with FDA
finance.yahoo.com/news/...ces-track-begin-phase-113000927.html

das es von Bekanntgabe der Phase 2 Ergebnisse bis Start Phase 3, (wenns denn mal so kommen sollte) fast 2 Jahre ins Land gezogen sind. Verdammt lange finde ich.

Derma Sciences Reports Third Quarter 2012 Financial Results

-Net Sales up 24%, Advanced Wound Care Sales up 67%, Traditional Wound Care Sales up 9%-

-DSC127 Drug Program on Track for Phase 3 Start by Year End-

Conference call begins at 11:00 a.m. Eastern time today
finance.yahoo.com/news/...reports-third-quarter-123000442.html

nach KE..die Verkäufer kommen wieder billiger an Ihre Teile.

finance.yahoo.com/news/...s-commencement-public-210400175.html

Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock

www.ir.dermasciences.com/profiles/investor/...amp;Category=440

als ich das erste mal gekauft habe waren wir noch bei ca 7 Mio

Ich hoffe das wars jetzt. Resultate der Phase 3 die demnächst beginnen soll, wollen sie in Q1 2015 kommunizieren.

Also erstmal nix mit Rakete hier? Einen eventuellen Kursschub könnte es geben wenn sie einen guten Partner außerhalb der USA finden und die Indikationen ausgeweitet werden. Aber da warte ich auch schon lange drauf.

finance.yahoo.com/news/...s-reports-2012-fourth-110000118.html

finance.yahoo.com/news/...eports-second-quarter-113000615.html

finance.yahoo.com/news/...unces-record-revenues-120000862.html